Justia Patents Opinion Summaries

Stryker’s patents concern pulsed lavage devices that deliver pressurized irrigation for medical therapies, including cleaning wounds. In 1993 Stryker applied for the patents and began to market portable, battery powered, handheld devices. They include suction and discharge tubes. Older systems required a central power source and external mechanical pumps and needed to be wheeled around the hospital. The patents issued in 2000, 2001 and 2006. Zimmer introduced its first portable pulsed lavage device in 1996; its Pulsavac Plus achieved $55 million in annual sales in 2007. Stryker sued Zimmer. The district court found infringement of two patents. The jury found infringement of one claim 2 of the third patent; that all the asserted claims were valid; that Zimmer had willfully infringed all three patents; and that Stryker had marked substantially all of its products that commercially embodied the patents during the period it sought damages, under 35 U.S.C. 287(a). The court awarded $70 million in lost profits plus attorneys’ fees, and imposed an injunction. The Federal Circuit affirmed that the patents were valid and infringed, and the award of damages, but reversed the judgment that infringement was willful and vacated the award of treble damages and award of attorneys’ fees. View "Stryker Corp. v. Zimmer, Inc." on Justia Law

Plaintiffs own patents relating to the BRCA1 and BRCA2 genes, mutations of which are linked to hereditary breast and ovarian cancers. In prior litigation, the Supreme Court held that claims of one of the patents were drawn to patent-ineligible subject matter because the isolated DNA strands were natural phenomena. Generic competitors entered the market for kits to test for susceptibility to particular kinds of cancer. Plaintiffs sought a preliminary injunction, alleging infringement of 66 claims across 15 patents. The district court denied a preliminary injunction. The four composition of matter claims on appeal are directed to primers, which are “short, synthetic, single-stranded DNA molecule[s] that bind[] specifically to . . . intended target nucleotide sequence[s].” The court held these were likely patent ineligible because they claim “products of nature.” The method claims on appeal involve comparisons between the wild-type BRCA sequences with the patient’s BRCA sequences. The court reasoned that these were likely ineligible because the only “inventive concepts” are the patent-ineligible naturally occurring BRCA1 and BRCA2 sequences themselves; the other steps are conventional activities, uniformly employed by those working with DNA. The Federal Circuit affirmed, finding that the claims are directed to ineligible subject matter under 35 U.S.C. 101. View "Univ. of Ut. Research Found. v. Ambry Genetics Corp." on Justia Law

ABB designs, produces, and sells exhaust-gas turbochargers and turbocharger parts, primarily for use in large, ocean-going vessels and in power plants. In 2012, ABB filed suit, accusing TurboUSA, Inc., and TurboNed Service B.V. of infringing two of ABB’s turbocharger-related patents. Claiming that the infringement was willful, ABB alleged that its former employee had improperly obtained and transferred to TurboUSA confidential information relating to ABB parts embodying its patented inventions. After filing its original complaint, ABB received information that, it alleges, suggested that Hans Franken, who worked for ABB until 1986 and is TurboNed’s former owner and TurboUSA’s current indirect owner, and his son Willem, who is TurboUSA’s current president, collaborated in the covert misappropriation of ABB’s trade secrets concerning the design, manufacture, servicing, and pricing of ABB’s turbochargers and parts, and added claims of misappropriation of trade secrets under Fla. Stat. 688.001–688.009 and of civil conspiracy to misappropriate trade secrets. Before discovery, the district court dismissed for failure to state a claim. The Federal Circuit reversed, concluding that the court relied on judgments about the merits that go beyond what is authorized at the complaint stage. View "ABB Turbo Sys. AG v. TurboUSA, Inc." on Justia Law

The patents at issue relate DNA testing, specifically to multiplex amplification of short tandem repeat (STR) loci and claim methods or kits for simultaneously determining the alleles present in a set of STR loci from DNA samples, comprising: obtaining a DNA sample; selecting a set of loci of the DNA sample to amplify, including at least the specific loci recited in the claim; co-amplifying the selected loci in a multiplex amplification reaction; and evaluating the amplified alleles to determine the number of STR present at each loci. The district court entered judgment that the asserted claims were not invalid for lack of enablement and obviousness and that certain accused products did not infringe either the Promega patents the Tautz patent, vacating a verdict of damages and willful infringement. The Federal Circuit held that LifeTech was not licensed for all uses of the asserted patents under an agreement with Promega and, therefore, reversed with respect to infringement (under 35 U.S.C. 271(a) and 35 U.S.C. 271(f)(1)), and remanded for determination of damages. The Federal Circuit held that the asserted claims of the Promega patents are invalid for lack of enablement. View "Promega Corp. v. Life Tech. Corp." on Justia Law

The 187 patent was assigned to the Foundation in February, 2001. In October, the Foundation’s attorney, responsible for prosecution of the patent filed a statutory disclaimer (37 C.F.R. 1.321(a)), for the entire term of all claims and requesting that it be duly recorded. In December, that attorney sought (37 C.F.R. 1.182) to withdraw the disclaimer, stating that it was not filed in the context of litigation or an assertion of double patenting, and had not yet been made public or entered into the PTO’s Patent Application Information Retrieval (PAIR) database or paper prosecution file. The PTO denied the petition, stating that mechanisms available to correct a patent “are not available to withdraw or otherwise nullify the effect of a recorded terminal disclaimer.” The disclaimer appeared on PAIR. The Foundation sought reconsideration, referencing “newly discovered evidence” that the disclaimer was unauthorized. The PTO denied the petition. The district court directed PTO “to withdraw the disclaimer, absent a finding that the Foundation actually authorized its filing.” The Federal Circuit reversed. PTO did not abuse its discretion in declining to use any inherent authority that it might have in withdrawing a disclaimer that the attorney of record filed in accordance with PTO regulations. View "Japanese Found. for Cancer Research v. Lee" on Justia Law

In 1997, Memorylink’s founders approached Motorola about jointly developing a handheld camera that could wirelessly transmit and receive video signals. After a successful demonstration, they sent Motorola a letter, agreeing “that any patents would be jointly owned by Motorola and Memorylink,” agreeing that Motorola should “head up the patent investigation,” and providing a “Wireless Multimedia Core Technology Overview for Patent Review” Motorola’s attorney sent a letter concerning the patent applications, stating an understanding that the inventors were Memorylink’s founders and Motorola employees Schulz and Wyckoff. A proposed patent filing agreement was enclosed. The named inventors signed an invention disclosure and an Assignment of rights to Motorola and Memorylink. Memorylink sued Motorola in 2008, alleging patent infringement and torts sounding in fraud, and seeking a declaration that the Assignment was void for lack of consideration. The district court rejected Memorylink’s argument that its claims did not accrue until an inventorship problem was discovered and dismissed most claims, reasoning that Memorylink should have known that the Motorola employees were not co-inventors in 1998, so that its claims were untimely. The court found that the consideration issue was a contract claim, not time-barred, but granted Motorola summary judgment. The Federal Circuit affirmed. View "Memorylink Corp. v. Motorola Solutions, Inc." on Justia Law

Sandoz sought a declaratory judgment that two patents, exclusively licensed to Amgen, were invalid and unenforceable and would not be infringed if Sandoz uses, offers to sell or sells, or imports a drug product “biosimilar” to Amgen’s Enbrel®, which is a drug used for treatment of rheumatoid arthritis. Sandoz has not yet filed an application for approval of its contemplated product by the FDA and had only begun certain testing required for its contemplated FDA filing. The district court dismissed the case, determining that no Article III controversy (yet) existed between the parties and also that the suit was barred by the Biologics Price Competition and Innovation Act of 2009 (BPCIA), 42 U.S.C. 262. The Federal Circuit affirmed, concluding that Sandoz did not allege an injury of sufficient immediacy and reality to create subject matter jurisdiction. The court did not address interpretation of the BPCIA. View "Sandoz, Inc. v. Amgen, Inc." on Justia Law

DDR’s patents are directed to generating a web page that combines visual elements of a “host” website with content of a third-party merchant. Prior art allowed third-party merchants to “lure the [host website’s] visitor traffic away” from the host website; visitors would be taken to the merchant’s website upon clicking the merchant’s advertisement. The patents disclose that, on activation of a third-party hyperlink on a host website, instead of taking visitors to the merchant’s website, the system generates and directs them to a page that displays product information from the merchant, but retains the host website’s “look and feel.” DDR sued NLG, a travel agency that sells cruises online in partnership with travel websites and cruise lines, asserting infringement by providing a system for cruise-oriented (host) websites that allows visitors to book cruises on cruise lines (merchants). In reexamination of the patents based on prior art, the PTO confirmed the patents’ validity. The parties stipulated to construction of terms, including “look and feel” and “visually perceptible elements.” The district court found the patents not invalid and infringed. The Federal Circuit affirmed except with respect to the 572 patent, which it found to be anticipated as a matter of law. View "DDR Holdings, LLC v. Hotels.Com, L.P." on Justia Law

Tyco sued alleging that Ethicon’s ultrasonic cutting and coagulating surgical devices infringed certain claims in three of its patents. The district court held that certain claims of those patents would not have been obvious under 35 U.S.C. 103, but that the other asserted claims are anticipated under 35 U.S.C. 102(g). The Federal Circuit upheld the section102(g) findings, but held that the section 103 determination was improper, including the court’s decision to exclude the section 102(g) prior art from the obviousness analysis. View "Tyco Healthcare Grp., LP v. Ethicon Endo-Surgery, Inc." on Justia Law

Interoperability, enabling electronic devices to charge and connect to the wireless Internet anywhere, requires compliance with technical standards. The Institute of Electrical and Electronics Engineers (IEEE) publishes the prevailing wireless internet standard. Creating such standards involves collaboration; the chosen standard may include technology developed by different parties, which may be covered by patents. Because the standard requires that devices utilize specific technology, compliant devices necessarily infringe certain claims in “standard essential patents” (SEPs), which can inhibit widespread adoption of a standard. IEEE asks SEP owners to pledge that they will grant licenses to an unrestricted number of applicants on “reasonable and nondiscriminatory” (RAND) terms. Ericsson’s patents are SEPs for IEEE’s standard. Ericsson promised IEEE it would offer licenses at a RAND rate. The accused infringers produce devices incorporating Intel’s wireless chips. Dell claimed that it has a license based on its prior agreement with Ericsson’s subsidiary. In Ericsson’s infringement suit, the court rejected that claim and found that D-Link infringed three Ericsson patents; held that the 625 patent was valid over a prior art; found that Intel violated its obligation to negotiate a royalty rate in good faith; and awarded Ericsson $10 million (15 cents per infringing device). The Federal Circuit affirmed two infringement findings, but reversed as to another; affirmed that the 625 patent was not invalid; and vacated the damages and ongoing royalty awards. View "Ericsson, Inc. v. D-Link Sys., Inc." on Justia Law